Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Ocugen Inc OCGN

Healthcare Biotechnology
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:OCGN)

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

GlobeNewswire 1 day ago

Ocugen Announces Compelling Preliminary Data for OCU410-a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

GlobeNewswire 2 days ago

Ocugen Provides Business Update with Third Quarter 2024 Financial Results

GlobeNewswire 13 days ago

Ocugen Secures $30 Million in Debt Funding

GlobeNewswire November 7, 2024

Attention Ocugen, Inc. (OCGN) Shareholders: Grabar Law Office Investigates Claims on Your Behalf

Newsfile November 1, 2024

Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

GlobeNewswire October 28, 2024

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

GlobeNewswire October 22, 2024

Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results

GlobeNewswire October 17, 2024

Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit

GlobeNewswire October 10, 2024
View More News ››

Opinion & Analysis (NDAQ:OCGN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:OCGN)

Ocugen Announces European Medicines Agency Grants Orphan Med

NEWS: $OCGN Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate...
whytestocks - 1 day ago

Ocugen Announces OCU400-Modifier Gene Therapy-Phase 1/2 Data

JUST IN: $OCGN Ocugen Announces OCU400-Modifier Gene Therapy-Phase 1/2 Data Presentation at&#xA0;Retinal Cell and Gene Therapy...
whytestocks - April 29, 2024

Ocugen to Present on Modifier Gene Therapy Platform at Assoc

Just In: $OCGN Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual...
whytestocks - April 26, 2024

Ocugen to Participate in Fireside Chat at the Emerging Growt

News; $OCGN Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble...
whytestocks - April 12, 2024

Ocugen, Inc. Announces Dosing Completion of Subjects with St

Breaking News: $OCGN Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial...
whytestocks - February 22, 2024

Kevin Harrington Discusses FSD Pharma

<< View Post To Watch Video >> I believe this new product will aid society in reducing the number of alcohol-related...
Richardson35 - April 13, 2023
View more Bullboard ››

Interactive Capital Partners Corporation

Interactive Capital Partners Corporation

View More »